The TEASE-1 trial reveals gildeuretinol's potential to reduce vision loss in Stargardt disease, offering hope for future ...

The ranibizumab ocular implant (Susvimo) reduces the need for frequent intravitreal anti-VEGF injections in patients with neovascular age-related macular degeneration or diabetic macular edema, and ...

Boyer discusses a potential treatment for diabetic retinopathy and macular degeneration using suprachoroidal injections, ...

Results At 1 year, 28 658 patient eyes underwent a mean of 6.4 anti-VEGF injections, gaining a mean of +4.2 letters (95% confidence interval for mean gain: +4.0 to +4.5 letters, p<0.001). When ...

The Food and Drug Administration (FDA) has approved Susvimo ® (ranibizumab injection) for the treatment of patients with ...

The new offering, designed specifically for prefilled syringes used in various applications, complements its 1 mL ImProject ...